Meningococcal Conjugate Vaccine (MenACWY)
- Direct contact with large droplet respiratory secretions transmission
- Incubation 3-7 days
- Inactivated conjugate vaccine, containing N. meningitidis serogroups A, C, Y, and W-135
- Menactra® – Minimum age 9 months
- Menveo® – Minimum age 2 months bivalent meningococcal conjugate vaccine and Haemophilus influenza type b conjugate vaccine Hib-MenACWY approved for use in ages 6 weeks through 18 months.
- Menveo® – Newly licensed Menveo one-vial (all liquid) formulation should not be administered before age 10 years.
- MenQuadfi® – Minimum age 2years
Dose & Route
0.5 mL given IM
- Routine: 2-dose series at 11-12 years, 16 years
- Catch-up: Age 13-15 years 1-dose now and booster at age 16-18 years (minimum interval 8 weeks).
- Age 16-18 years: 1-dose
*For booster doses among persons with high-risk conditions refer to http://www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm
- Anatomical or functional asplenia (including sickle cell disease)
- HIV infection
- Persistent complement component deficiency
- Complement Inhibitor
- Eculizumab or Ravulizumab use
- Travel to or live in countries where meningococcal disease is hyperendemic or epidemic meningococcal disease, including countries in the African meningitis belt or during Hajj
- At risk from a meningococcal disease outbreak attributed to serogroup A, C, W, or Y
- Microbiologists routinely exposed to Neisseria meningitidis
- MenACWY may be administered during pregnancy if indicated.
- Because vaccinees may develop syncope, sometimes resulting in falling with injury, observation for 15 minutes after administration is recommended. If syncope develops, patients should be observed until the symptoms resolve.
- Menactra should be administered either before or at the same time as DTaP.